Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial

Diabetes Research and Clinical Practice

Volumn 94, Issue 2, 2011, Pages 217-224

  Yang, Wenying ^a   Pan, Chang Yu ^b   Tou, Conrad ^c   Zhao, June ^c   Gause Nilsson, Ingrid ^d  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

DPP 4 inhibitor; Glycemic control; Incretins; Metformin; Saxagliptin

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; PLACEBO; SAXAGLIPTIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; CONTROLLED STUDY; DIABETES CONTROL; DIARRHEA; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FRACTURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOGLYCEMIA; INFECTION; LIFESTYLE MODIFICATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADAMANTANE; ADULT; AGED; ANALYSIS OF VARIANCE; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 81255160603     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.07.035     Document Type: Article

References (26)

1. Asian-Pacific Type 2 Diabetes Policy Group. Type 2 diabetes: practical targets and treatments. 4th ed. Melbourne/Singapore: International Diabetes Institute (IDI)/In Vivo Communications (Asia) Pte Limited. ; 2005 [accessed 7.07.10]. http://www.idf.org/webdata/docs/T2D_practical_tt.pdf.
2. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362(12):1090-1101.
3. International Diabetes Federation. IDF diabetes atlas. 4th ed. [accessed 7.07.10]. http://www.diabetesatlas.org/.
4. Chan J.C., Malik V., Jia W., Kadowaki T., Yajnik C.S., Yoon K.-H., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009, 301(20):2129-2140.
5. Seino Y., Yamada T. Heterogeneity in pathogenesis of NIDDM and recent advances in research of diabetogenic genes [in Japanese]. Nippon Rinsho 1994, 52(10):2686-2692.
6. Qian L., Xu L., Wang X., Fu X., Gu Y., Lin F., et al. Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation. Diabetes Metab Res Rev 2009, 25(2):144-149.
7. International Diabetes Federation. Clinical guidelines task force, global guideline for type 2 diabetes. Brussels, Belgium: International Diabetes Federation. ; 2005 [accessed 7.07.10]. http://www.idf.org/webdata/docs/IDF%2520GGT2D.pdf.
8. DeFronzo R.A. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus [Banting Lecture]. Diabetes 2009, 58(4):773-795.
9. Rodbard H.W., Jellinger P.S., Davidson J.A., Einhorn D., Garber A.J., Grunberger G., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15(6):540-559.
10. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26(10):2929-2940.
11. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006, 60(11):1454-1470.
12. Nauck M.A., Heimesaat M.M., Ørskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91(1):301-307.
13. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368(9548):1696-1705.
14. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48(15):5025-5037.
15. Rosenstock J., Aguilar-Salinas C., Klein E., Nepal S., List J., Chen R. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009, 25(10):2401-2411.
16. Hinke S.A., Kühn-Wache K., Hoffmann T., Pedersen R.A., McIntosh C.H.S., Demuth H.-U. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002, 291(5):1302-1308.
17. Yasuda N., Inoue T., Nagakura T., Yamazaki K., Kira K., Saeki T., et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002, 298(5):779-784.
18. DeFronzo R.A., Hissa M.N., Garber A.J., Gross J.L., Duan R.Y., Ravichandran S., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009, 32(9):1649-1655.
19. Jadzinsky M., Pfützner A., Paz-Pacheco E., Xu Z., Allen E., Chen R., et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009, 11(6):611-622.
20. Göke B., Gallwitz B., Eriksson J., Hellqvist Å., Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010, 64(12):1619-1631. for the D1680C00001 Investigators.
21. Scheen A.J., Charpentier G., östgren C.J., Hellqvist Å., Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010, 26(7):540-549.
22. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27(6):1487-1495.
23. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29(12):2638-2643. for the Sitagliptin Study 020 Group.
24. Ahrén B., Gomis R., Standl E., Mills D., Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27(12):2874-2880.
25. Bosi E., Camisasca R.P., Collober C., Rochotte E., Garber A.J. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007, 30(4):890-895.
26. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853.